Follow the 엔젠바이오 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 엔젠바이오 has recorded 86 insider filings. Market capitalisation: €21.5bn. The latest transaction was filed on 10 July 2026 (Other). Among the most active insiders: 최대출. All data is accessible without an account.
81
Insider Decl.
n/a
Thresholds
n/a
27 ops.
Buy Volume
n/a
21 ops.
Sell Volume
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,491 of 29,062 companies
9.8
score / 100
Value
6
Quality
13
FCF yld-45%
Earn yld-29%
EV/EBITDA·
ROE-29%
Gross mgn18%
Net mgn-26%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Enzenbio es una empresa del sector de la salud y farmacéutico, que cotiza en el mercado XKRX. Se enfoca en el desarrollo de soluciones innovadoras para el diagnóstico y tratamiento de enfermedades.